Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $17
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 01 2024
0mins
Should l Buy TDOC?
Source: Benzinga
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 5.100
Low
7.50
Averages
8.91
High
12.00
Current: 5.100
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TELADOC HEALTH: OPPENHEIMER LOWERS TARGET PRICE FROM $12 TO $7
- Target Price Adjustment: The target price for Teladoc Health has been cut from $12 to $7.
- Market Impact: This adjustment reflects a significant change in market expectations for the company's performance.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
Teladoc Reports Strong Q4 Results Exceeding Expectations
- Performance Beat: Teladoc reported a Q4 loss of $0.14 per share, better than the market's expectation of a $0.18 loss, indicating improvements in cost control and operational efficiency, which boosts investor confidence.
- Sales Growth: The company achieved sales of $642.269 million, surpassing market estimates of $635.235 million, suggesting sustained demand in the healthcare sector that could drive future market share gains.
- 2026 Outlook: Teladoc anticipates a FY2026 GAAP loss between $1.10 and $0.70, lower than the market estimate of $0.76, reflecting the company's confidence in its future financial performance, potentially attracting more investor interest.
- Stock Price Surge: Teladoc shares rose 13.5% to $5.28 on Thursday, reflecting a positive market reaction to the company's results, which may support future financing and strategic investments.
See More
Teladoc Health Reports Strong Q4 2025 Results, Upgraded by BofA
- Strong Earnings Beat: Teladoc Health reported Q4 2025 revenue of $642.3 million, exceeding consensus by $6.9 million, showcasing significant progress in its Integrated Care segment, which generated $409.1 million with approximately 5% YoY growth.
- BetterHelp Business Outlook: Despite a ~7% YoY decline in BetterHelp revenue to $233.2 million, BofA analyst Allen Lutz noted that transitioning from a direct-to-consumer model to insurance coverage would reduce marketing intensity and improve margins, enhancing overall profitability.
- Market Valuation Upside: Lutz projected that if BetterHelp can shift 50-60% of its revenue to insurance coverage by 2028, it could support an enterprise value of $1.2 billion, significantly surpassing Teladoc's current valuation, indicating strong market recognition of its growth potential.
- Stock Rating Upgrade: BofA upgraded Teladoc from Neutral to Buy, maintaining a $7 price target, reflecting optimism about its future performance and market prospects, particularly in AI advancements and international expansion.
See More
Teladoc Health Reports Q4 Earnings Beat with 2026 Guidance
- Earnings Beat: Teladoc Health reported a Q4 GAAP EPS of -$0.14, surpassing expectations by $0.04, indicating positive signals in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $642.27 million, exceeding forecasts by $6.94 million, demonstrating its competitive position and sustained customer demand in the market.
- Future Outlook: Teladoc's guidance figures for 2026 reflect optimistic growth expectations, although specific numbers were not disclosed, the market generally holds a positive view on its future development.
- Market Reaction: Despite the earnings beat, analysts downgraded Teladoc's rating, reflecting concerns over its low valuation, which may impact investor confidence.
See More
Teladoc Health Q4 2025 Results Beat Expectations
- Strong Earnings Report: Teladoc Health's Q4 2025 financial results surpassed expectations with revenue of $642.27 million, exceeding the consensus estimate of $635.33 million, demonstrating resilience in a competitive healthcare market.
- International Revenue Growth: The company experienced a 19% year-over-year increase in international revenue, effectively offsetting a 3% decline in U.S. revenue, indicating the success of Teladoc's global expansion strategy and enhancing overall financial stability.
- Future Guidance: Teladoc projects 2026 revenue between $2.47 billion and $2.587 billion, although slightly below the consensus of $2.55 billion, it still reflects the company's confidence in future growth, particularly in international markets.
- Cash Flow Status: As of the end of 2025, Teladoc's cash and cash equivalents stood at approximately $781.1 million, a significant decrease from $1.3 billion on December 31, 2024, highlighting financial pressures in operations and investments, necessitating close attention to future cash management strategies.
See More
TELADOC HEALTH: OPPENHEIMER LOWERS TARGET PRICE FROM $12 TO $7
- Target Price Adjustment: The target price for Teladoc Health has been cut from $12 to $7.
- Market Impact: This adjustment reflects a significant change in market expectations for the company's performance.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
Teladoc Reports Strong Q4 Results Exceeding Expectations
- Performance Beat: Teladoc reported a Q4 loss of $0.14 per share, better than the market's expectation of a $0.18 loss, indicating improvements in cost control and operational efficiency, which boosts investor confidence.
- Sales Growth: The company achieved sales of $642.269 million, surpassing market estimates of $635.235 million, suggesting sustained demand in the healthcare sector that could drive future market share gains.
- 2026 Outlook: Teladoc anticipates a FY2026 GAAP loss between $1.10 and $0.70, lower than the market estimate of $0.76, reflecting the company's confidence in its future financial performance, potentially attracting more investor interest.
- Stock Price Surge: Teladoc shares rose 13.5% to $5.28 on Thursday, reflecting a positive market reaction to the company's results, which may support future financing and strategic investments.
See More
Teladoc Health Reports Strong Q4 2025 Results, Upgraded by BofA
- Strong Earnings Beat: Teladoc Health reported Q4 2025 revenue of $642.3 million, exceeding consensus by $6.9 million, showcasing significant progress in its Integrated Care segment, which generated $409.1 million with approximately 5% YoY growth.
- BetterHelp Business Outlook: Despite a ~7% YoY decline in BetterHelp revenue to $233.2 million, BofA analyst Allen Lutz noted that transitioning from a direct-to-consumer model to insurance coverage would reduce marketing intensity and improve margins, enhancing overall profitability.
- Market Valuation Upside: Lutz projected that if BetterHelp can shift 50-60% of its revenue to insurance coverage by 2028, it could support an enterprise value of $1.2 billion, significantly surpassing Teladoc's current valuation, indicating strong market recognition of its growth potential.
- Stock Rating Upgrade: BofA upgraded Teladoc from Neutral to Buy, maintaining a $7 price target, reflecting optimism about its future performance and market prospects, particularly in AI advancements and international expansion.
See More
Teladoc Health Reports Q4 Earnings Beat with 2026 Guidance
- Earnings Beat: Teladoc Health reported a Q4 GAAP EPS of -$0.14, surpassing expectations by $0.04, indicating positive signals in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $642.27 million, exceeding forecasts by $6.94 million, demonstrating its competitive position and sustained customer demand in the market.
- Future Outlook: Teladoc's guidance figures for 2026 reflect optimistic growth expectations, although specific numbers were not disclosed, the market generally holds a positive view on its future development.
- Market Reaction: Despite the earnings beat, analysts downgraded Teladoc's rating, reflecting concerns over its low valuation, which may impact investor confidence.
See More
Teladoc Health Q4 2025 Results Beat Expectations
- Strong Earnings Report: Teladoc Health's Q4 2025 financial results surpassed expectations with revenue of $642.27 million, exceeding the consensus estimate of $635.33 million, demonstrating resilience in a competitive healthcare market.
- International Revenue Growth: The company experienced a 19% year-over-year increase in international revenue, effectively offsetting a 3% decline in U.S. revenue, indicating the success of Teladoc's global expansion strategy and enhancing overall financial stability.
- Future Guidance: Teladoc projects 2026 revenue between $2.47 billion and $2.587 billion, although slightly below the consensus of $2.55 billion, it still reflects the company's confidence in future growth, particularly in international markets.
- Cash Flow Status: As of the end of 2025, Teladoc's cash and cash equivalents stood at approximately $781.1 million, a significant decrease from $1.3 billion on December 31, 2024, highlighting financial pressures in operations and investments, necessitating close attention to future cash management strategies.
See More
